SKYE MEXC RealStocks
Own real SKYE shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 08:17:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Skye Bioscience, Inc. (SKYE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.07, with a market capitalization of $4.07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.50 to $12.16. This page covers its latest market performance, valuation, price trends and company information.
$4.07M | |
$0.89 | |
$1.31 | |
$0.86 | |
$0.92 | |
159.38K | |
110.37K | |
-- | |
$12.16 | |
$0.50 | |
-- | |
-- |
Skye Bioscience, Inc. (SKYE) last closed at $1.07 as of 2026-11-13 00:56:00, up 20.78% ($0.19) from the previous close of $0.92.
During the latest regular trading session, SKYE traded between $0.86 and $1.31, with a volume of 159.38K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Skye Bioscience, Inc. (SKYE) moved from $1.14 to $1.07, representing a decline of 6.49% ($0.07).
The stock traded between $0.50 and $1.31 during the period. The latest price is near the upper end of the 7-day range, indicating strong downward.
The average daily volume was 299.19 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 4.9%
SKYE is currently trading at $1.07, placing it 4.9% of the way from its 52-week low of $0.50 to its 52-week high of $12.16. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Skye Bioscience, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Skye Bioscience, Inc. (SKYE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to SKYE, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between SKYE shares and USD.
SKYE Shares to USD
1.00 SKYE shares = 1.066 USD
Calculations are estimates based on the latest available price and are for reference only.